Evommune Narrows Loss on Revenue Jump, Secures $65M in New Funding

TL;DR

**EVMN is burning cash but a fresh $65M raise and growing license revenue offer a lifeline, making it a speculative buy for risk-tolerant biotech bulls.**

AI Summary

Evommune, Inc. reported a net loss of $40.6 million for the nine months ended September 30, 2025, an improvement from the $46.1 million net loss in the prior year period. License revenue significantly increased to $13.0 million for the nine months ended September 30, 2025, up from $7.0 million in the same period of 2024, including a $10.0 million contribution in the third quarter of 2025. Research and development expenses rose to $53.6 million for the nine months ended September 30, 2025, compared to $46.4 million in 2024, reflecting increased clinical trial activities for product candidates EVO756 and EVO301. The company's cash and cash equivalents increased to $26.8 million as of September 30, 2025, from $16.3 million at December 31, 2024, primarily due to $65.2 million in proceeds from the issuance of Series C convertible preferred stock. Total current assets grew to $81.9 million from $74.0 million, while total current liabilities decreased substantially to $10.4 million from $28.0 million, largely due to the elimination of a $8.9 million convertible preferred stock forward liability. Despite increased revenue, the company continues to operate at a significant loss and highlights the need for substantial additional funding to advance its product candidates.

Why It Matters

Evommune's ability to secure $65.2 million in Series C convertible preferred stock funding is critical for its continued operations and advancing its drug pipeline, particularly EVO756 and EVO301, in a highly capital-intensive biotechnology sector. The significant increase in license revenue to $13.0 million suggests potential validation of its early-stage assets, which could attract further partnerships and investment. For investors, the reduced net loss and strengthened cash position offer a glimmer of stability, but the persistent high R&D expenses and the explicit need for 'substantial additional funding' underscore the inherent risks in a pre-commercial biotech. Competitively, successful clinical trial progression is paramount for Evommune to differentiate itself and capture market share in therapeutic areas it targets.

Risk Assessment

Risk Level: high — Evommune explicitly states, 'We will need substantial additional funding in order to maintain our operations and advance the development and commercialization of our product candidates.' The company reported a net loss of $40.6 million for the nine months ended September 30, 2025, and cash used in operating activities was $59.7 million, indicating a significant cash burn rate despite the recent $65.2 million capital raise.

Analyst Insight

Investors should monitor Evommune's progress on its clinical trials for EVO756 and EVO301 closely, as these are critical for future value creation. Given the high cash burn and stated need for 'substantial additional funding,' investors should also assess the company's ability to secure further financing without significant dilution, and consider this a high-risk, high-reward speculative investment.

Financial Highlights

debt To Equity

N/A

revenue

$13.0M

operating Margin

-387.3%

total Assets

$84.5M

total Debt

$10.7M

net Income

-$40.6M

eps

-$8.07

gross Margin

N/A

cash Position

$26.8M

revenue Growth

+85.7%

Revenue Breakdown

Key Numbers

• $40.6M — Net Loss (Reduced from $46.1M in prior year period for nine months ended Sep 30, 2025)
• $13.0M — License Revenue (Increased from $7.0M in prior year period for nine months ended Sep 30, 2025)
• $65.2M — Proceeds from Preferred Stock (New capital raised in nine months ended Sep 30, 2025)
• $53.6M — Research and Development Expenses (Increased from $46.4M in prior year period for nine months ended Sep 30, 2025)
• $26.8M — Cash and Cash Equivalents (Increased from $16.3M at Dec 31, 2024)
• $59.7M — Net Cash Used in Operating Activities (Increased from $39.7M in prior year period for nine months ended Sep 30, 2025)
• $10.4M — Total Current Liabilities (Decreased from $28.0M at Dec 31, 2024)
• $8.9M — Change in fair value of convertible preferred stock forward (Positive impact on other income, net for nine months ended Sep 30, 2025)
• 31,524,093 — Common Stock Shares Outstanding (As of December 10, 2025)
• $8.07 — Basic and Diluted Net Loss Per Share (For the three months ended September 30, 2025, improved from $10.47 in prior year)

Key Players & Entities

• Evommune, Inc. (company) — Registrant in 10-Q filing
• SEC (regulator) — Securities and Exchange Commission
• New York Stock Exchange (regulator) — Exchange where EVMN common stock is registered
• EVO756 (company) — Most-advanced product candidate
• EVO301 (company) — Most-advanced product candidate
• $40.6 million (dollar_amount) — Net loss for nine months ended September 30, 2025
• $13.0 million (dollar_amount) — License revenue for nine months ended September 30, 2025
• $65.2 million (dollar_amount) — Proceeds from issuance of convertible preferred stock
• $53.6 million (dollar_amount) — Research and development expenses for nine months ended September 30, 2025
• $26.8 million (dollar_amount) — Cash and cash equivalents as of September 30, 2025

FAQ

Risk Factors

• Substantial Additional Funding Required [high — financial]: The company reported a net loss of $40.6 million for the nine months ended September 30, 2025, and highlights the need for substantial additional funding to advance its product candidates. This indicates a continued reliance on external capital to sustain operations and development.
• Increased R&D Expenses [medium — operational]: Research and development expenses increased to $53.6 million for the nine months ended September 30, 2025, from $46.4 million in the prior year period. This rise is attributed to increased clinical trial activities for product candidates EVO756 and EVO301, suggesting higher operational costs associated with drug development.
• Dependence on Preferred Stock Financing [medium — financial]: The company raised $65.2 million in proceeds from the issuance of Series C convertible preferred stock. While this bolstered cash reserves, it also signifies a reliance on equity financing, which can dilute existing shareholders.
• Clinical Trial Success Dependency [high — regulatory]: The company's advancement of product candidates EVO756 and EVO301 is heavily dependent on the success of ongoing clinical trials. Any setbacks or failures in these trials could significantly impact future revenue and the company's ability to secure further funding.

Industry Context

Evommune operates in the biotechnology sector, a highly competitive and capital-intensive industry focused on developing novel therapeutics. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory oversight. Success often hinges on the efficacy and safety of drug candidates demonstrated through clinical trials.

Regulatory Implications

As a clinical-stage biotechnology company, Evommune is subject to rigorous regulatory scrutiny from bodies like the FDA. The success of its product candidates, EVO756 and EVO301, is contingent upon meeting regulatory requirements for safety and efficacy through clinical trials. Any delays or adverse findings in these trials could have significant financial and operational repercussions.

What Investors Should Do

1. Monitor R&D spending and clinical trial progress.
2. Assess future financing needs and strategies.
3. Analyze the growth drivers of license revenue.

Key Dates

• 2025-09-30: Nine months ended September 30, 2025 — Reported net loss of $40.6M, improved license revenue of $13.0M, and increased R&D expenses of $53.6M. Cash position strengthened to $26.8M.
• 2024-12-31: As of December 31, 2024 — Cash and cash equivalents were $16.3M, and total current liabilities were $28.0M, including an $8.9M convertible preferred stock forward liability.
• 2025-09-30: As of September 30, 2025 — Cash and cash equivalents increased to $26.8M. Total current liabilities decreased significantly to $10.4M.

Glossary

License Revenue

Revenue generated from granting rights to intellectual property, such as patents or technology, to other parties. (A key revenue stream for Evommune, showing significant growth in the period.)

Research and Development Expenses

Costs incurred in the process of discovering, developing, and testing new products or technologies. (Represents a significant investment for Evommune in advancing its product candidates.)

Convertible Preferred Stock

A class of preferred stock that can be converted into a specified number of common stock shares. (Evommune has issued Series C convertible preferred stock, raising significant capital.)

Convertible Preferred Stock Forward

A financial instrument that obligates the company to issue or repurchase convertible preferred stock at a future date, often at a predetermined price. (A liability that was present in the prior period and has since been eliminated, impacting current liabilities.)

Net Loss Per Share

The portion of a company's profit or loss allocated to each outstanding share of common stock. (Indicates the company's profitability on a per-share basis, showing a loss for the period.)

Year-Over-Year Comparison

Evommune has shown a positive trend in reducing its net loss to $40.6 million for the nine months ended September 30, 2025, compared to $46.1 million in the prior year. License revenue has significantly increased to $13.0 million, up from $7.0 million. However, Research and Development expenses have also risen to $53.6 million, reflecting increased investment in clinical trials. The company's cash position has improved substantially to $26.8 million, largely due to preferred stock issuance, while current liabilities have decreased significantly, partly due to the elimination of a convertible preferred stock forward liability.

Key Financial Figures

• $0.0001 — ch registered Common stock, par value $0.0001 per share EVMN New York Stock Excha

Filing Documents

• evmn-20250930.htm (10-Q) — 3027KB
• evmn-ex31_1.htm (EX-31.1) — 20KB
• evmn-ex31_2.htm (EX-31.2) — 22KB
• evmn-ex32_1.htm (EX-32.1) — 19KB
• 0001193125-25-315972.txt ( ) — 11306KB
• evmn-20250930.xsd (EX-101.SCH) — 1078KB
• evmn-20250930_htm.xml (XML) — 2483KB

Financial Statements (unaudited)

Financial Statements (unaudited) 1 Condensed Consolidated Balance Sheets (unaudited) 1 Condensed Consolidated Statements of Operations (unaudited) 2 Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit (unaudited) 3 Condensed Consolidated Statements of Cash Flows (unaudited) 5 Notes to Condensed Consolidated Financial Statements (unaudited) 6 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 19 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 26 Item 4.

Controls and Procedures

Controls and Procedures 26 PART II. OTHER INFORMATION 27 Item 1.

Legal Proceedings

Legal Proceedings 27 Item 1A.

Risk Factors

Risk Factors 27 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 77 Item 3. Defaults Upon Senior Securities 77 Item 4. Mine Safety Disclosures 77 Item 5. Other Information 77 Item 6. Exhibits 77

Signatures

Signatures 79 i SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These statements are based on our management's belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements in this Quarterly Report on Form 10-Q include, but are not limited to, statements about: the success, cost and timing of our product development activities and clinical trials of our most-advanced product candidates, EVO756 and EVO301, and any future product candidates; the characteristics and potential advantages of our product candidates; our need to raise additional funding before we can expect to generate any revenues from product sales; our ability to obtain regulatory approval for our current or future product candidates that we may identify or develop; our ability to ensure adequate supply of our current or future product candidates; our ability to maintain third-party relationships necessary to conduct our business; our heavy dependence upon the success of our research to generate and advance additional product candidates; our ability to establish an adequate safety or efficacy profile for our current or future product candidates; the implementa

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION EVOMMUNE, INC. Condensed Conso lidated Balance Sheets (unaudited) (In thousands, except share and per share amounts) September 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 26,818 $ 16,255 Short-term investments 49,244 55,785 Prepaid expenses and other current assets 5,879 1,948 Total current assets 81,941 73,988 Operating lease right-of-use assets, net 160 472 Property and equipment, net 970 1,326 Restricted cash 1,412 208 Other non-current assets 61 61 Total assets $ 84,544 $ 76,055 Liabilities, Convertible Preferred Stock, and Stockholders' Deficit Current liabilities: Accounts payable $ 3,576 $ 8,264 Accrued liabilities 6,309 6,729 Operating lease liability, current portion 160 487 Convertible preferred stock forward — 8,928 Deferred revenue — 3,000 Other current liabilities 371 573 Total current liabilities 10,416 27,981 Other non-current liabilities 261 535 Total liabilities 10,677 28,516 Commitments and contingencies (Note 6) Convertible preferred stock: $ 0.0001 par value — 157,657,729 shares authorized at September 30, 2025 and December 31, 2024, respectively, 157,657,729 and 116,716,142 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively (Liquidation preference $ 275,611 and $ 210,328 at September 30, 2025 and December 31, 2024, respectively) 257,004 191,776 Stockholders' deficit: Common stock, par value $ 0.0001 — 223,593,879 shares authorized at September 30, 2025 and December 31, 2024, respectively; 1,554,965 and 1,551,420 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively — — Additional paid-in capital 9,679 7,982 Accumulated deficit ( 192,816 ) ( 152,219 ) Total stockholders' deficit ( 183,137 ) ( 144,237 ) Total liabilities, convertible

View Full Filing

View this 10-Q filing on SEC EDGAR